Interleukin-17 inhibitor, is it safer than tumor necrosis factor inhibitor?

Int J Rheum Dis. 2021 Jul;24(7):865-868. doi: 10.1111/1756-185X.14076.

Authors

Jinxian Huang¹, Lijun Zhang¹, James C-C Wei^{2

3

4}

Affiliations

¹ Division of Rheumatology, Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
² Department of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan.
³ Institute of Medicine, College of Medicine, Chung Shan Medical University, Taichung, Taiwan.
⁴ Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan.

PMID: 34241967
DOI: 10.1111/1756-185X.14076

No abstract available

Publication types

Editorial

MeSH terms

Arthritis / therapy*
Humans
Interleukin-17 / therapeutic use*
Osteoarthritis / therapy*
Tumor Necrosis Factor Inhibitors / therapeutic use*

Substances

IL17A protein, human
Interleukin-17
Tumor Necrosis Factor Inhibitors